These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. PHARMAC responds on tolterodine for overactive bladder. Moodie P N Z Med J; 2005 Feb; 119(1229):U1871. PubMed ID: 16498471 [No Abstract] [Full Text] [Related]
7. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. Athanasopoulos AA; Perimenis PS BJU Int; 2005 May; 95(7):1117-8. PubMed ID: 15839945 [No Abstract] [Full Text] [Related]
8. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z; Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327 [TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults. Roberts RG; Garely AD; Bavendam T Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389 [TBL] [Abstract][Full Text] [Related]
10. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. Dmochowski R; Kreder K; MacDiarmid S; Carlsson M; Guan Z BJU Int; 2007 Jul; 100(1):107-10. PubMed ID: 17552957 [TBL] [Abstract][Full Text] [Related]
11. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Takei M; Homma Y; Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131 [TBL] [Abstract][Full Text] [Related]
16. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed? Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055 [TBL] [Abstract][Full Text] [Related]
17. Tolterodine for treatment of overactive bladder. Kanofsky JA; Nitti VW Urol Clin North Am; 2006 Nov; 33(4):447-53, viii. PubMed ID: 17011380 [TBL] [Abstract][Full Text] [Related]
18. Medical treatment of overactive bladder. Rackley R; Wein A; Nelson D Mayo Clin Proc; 2001 Nov; 76(11):1179-80. PubMed ID: 11702910 [No Abstract] [Full Text] [Related]
19. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. Abrams P; Kaplan S; De Koning Gans HJ; Millard R J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601 [TBL] [Abstract][Full Text] [Related]
20. Patients with overactive bladders deserve better. Brenner B; Rice M N Z Med J; 2006 Feb; 119(1229):U1846. PubMed ID: 16498474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]